$MRK

Generating a unique summary for MRK…

AI-generated for information only — not investment advice.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Institutions hold 82.87% · insiders 0.06% · 4,874 institutions

Consensus score 1.78 (1 = strong buy, 5 = sell) · mean target 159.76

• CitigroupNeutralmain2026-10-12
• RBC CapitalSector Performmain2026-10-12
• Cantor FitzgeraldNeutralmain2026-10-08
• Morgan StanleyOverweightmain2026-10-07
• JP MorganOverweightmain2026-10-05
• ScotiabankSector Outperformmain2026-09-29
• HSBCBuymain2026-09-10
• Leerink PartnersOutperformmain2026-09-09
• GuggenheimBuymain2026-09-08
• Wells FargoOverweightmain2026-09-04

Next report: 2026-10-29

• 25-NSENotification filed by national security exchange to report the removal from listing and registration of matured2026-10-15Open
• 8-KCorporate Changes & Voting Matters2026-10-13Open
• 8-KCorporate Changes & Voting Matters2026-08-04Open
• 11-KAnnual report of employee stock purchase2026-06-24Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-29Open
• 8-KCorporate Changes & Voting Matters2026-05-28Open
• 8-KCorporate Changes & Voting Matters2026-05-22Open
• SC TO-T/ATender Offer/Acquisition Reports2026-05-05Open
• 10-QPeriodic Financial Reports2026-05-04Open
• 8-KCorporate Changes & Voting Matters2026-04-30Open

• Can Merck (MRK) Stay Undervalued If Cash Flow Keeps Growing?

  Merck has had a strong multi year run and is now back in the spotlight after fresh oncology headlines. This raises an important question for investors who focus on cash flows: Is the current share price mainly a reaction to recent news flow, or a reflection of what the company’s future cash generation can reasonably support? Merck has returned 92.3% over the past 5 years, so a lot of optimism is already embedded and the key issue is what level of cash flows can support that kind of...

  Sat, 24 Oct 2026 07:17:16 +0000

• Moderna stock extends losses as investors digest melanoma vaccine trial data

  Moderna shares ended Friday’s session modestly lower, extending the sharp losses recorded in the previous trading sessions.

  Fri, 23 Oct 2026 13:49:27 +0000

• Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?

  Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.

  Fri, 23 Oct 2026 20:08:43 +0000

• AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?

  When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.

  Fri, 23 Oct 2026 19:15:59 +0000

• Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

  Phase 2 results showed an objective response rate of 62.5%.

  Fri, 23 Oct 2026 17:04:14 +0000

• Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’

  In an interview with CNBC, Merck CEO Rob Davis said the company is confident it can deliver Intismeran at scale.

  Fri, 23 Oct 2026 15:33:59 +0000

• Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

  Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.

  Fri, 23 Oct 2026 13:17:53 +0000

• Moderna And Merck Cancer Vaccine Cuts Melanoma Death Risk By 42%

  Key Stats for Merck StockPrice change for Merck stock in last 6 months: 28%$MRK Stock Price as of Oct. 21: $14752-Week High: $157$MRK Stock Price Target: $159__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Moderna and Merck (MRK:NYSE) shared results from a large melanoma trial on Thursday.

  Fri, 23 Oct 2026 10:30:39 +0000